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Abstract
A lack of prospective studies has been a major barrier for assessing the role of the
microbiome in human health and disease on a population-wide scale. To address
this significant knowledge gap, we have launched a large-scale collection targeting
fecal and oral microbiome specimens from 20,000 women within the Nurses’ Health
Study II cohort (the Microbiome Among Nurses study, or Micro-N). Leveraging the
rich epidemiologic data that have been repeatedly collected from this cohort since
1989; the established biorepository of archived blood, urine, buccal cell, and tumor
tissue specimens; the available genetic and biomarker data; the cohort’s ongoing
follow-up; and the BIOM-Mass microbiome research platform, Micro-N furnishes
unparalleled resources for future prospective studies to interrogate the interplay
between host, environmental factors, and the microbiome in human health. These
prospectively collected materials will provide much-needed evidence to infer causality in microbiome-associated outcomes, paving the way toward development of
microbiota-targeted modulators, preventives, diagnostics and therapeutics. Here,
we describe a generalizable, scalable and cost-effective platform used for stool and
oral microbiome specimen and metadata collection in the Micro-N study as an example of how prospective studies of the microbiome may be carried out.
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ver the past decade, population-scale human microbiome
studies have provided tremendous evidence linking microorganisms in the gut and body-wide with various conditions
from gastroenterological and periodontal illnesses to cardiovascular,
neoplastic, respiratory, and neurologic disorders.1 However, the majority of human data are limited to cross-sectional studies, making it inherently challenging to differentiate cause from effect, and are prone
to reverse causation. Therefore, it is crucial to establish a biobank of
samples collected prior to the onset of disease from well-characterized young and middle-aged populations with long-term longitudinal
follow-up.2 Leveraging ongoing large cohort studies provides both a
relatively economical option and an ideal setting for the development
of such microbiome biobanks, owing to the established infrastructure
for biospecimen collection and outcome ascertainment, deep characterization of relevant risk factors, and complementary archival biospecimens that enable future linkage with the microbiome data.
Developing and deploying such platforms for microbiome epidemiology requires the establishment of reliable sample collection methods and associated metadata generation instruments.3,4 Here, we have
accomplished this in the context of the Nurses’ Health Study II (NHS
II), a leading epidemiologic cohort for studying risk factors and underlying mechanisms for chronic diseases among women.5 To extend
our knowledge about the role of the microbiome in health, we have
recently launched a large-scale prospective collection of fecal and oral
microbiome samples from 20,000 women in the NHS II, known as the
Microbiome Among Nurses (Micro-N) project. In this Perspective, we
provide an overview of the Micro-N project and the methods it adopts
to leverage generalizable population-scale microbiome collection protocols, which have subsequently been incorporated into the Harvard
Chan Microbiome in Public Health (HCMPH) Center’s BIOM-Mass (Biobank for Microbiome research in Massachusetts) platform. This platform provides generalizable, scalable, and cost-effective methods for
the conduct of prospective studies of the microbiome. We focus on
the considerations for several key elements in microbiome specimen
collection, including collection kit design, development of a comprehensive questionnaire for assessing potential major determinants of
the microbiome, as well as sample shipment, handling, and storage
protocols.
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Fig. 1 Overview of the Nurses’ Health Study II cohort. Qx: self-administered questionnaire covering a variety of lifestyle factors, health outcomes, and other healthrelated information; diet: assessed by validated food frequency questionnaire; blood
and urine samples were collected from participants in 1996–1999 and again in a
subset of those women in 2010–2011; buccal cell samples were collected in 2004–
2006 from participants that did not provide blood samples; the collection of microbiome samples began in 2019. Tissue specimens are continuously collected from
participants diagnosed with incident cancers or premalignant lesions during the
ongoing follow-up.

Overview of the NHS II Cohort
The NHS II is an ongoing prospective cohort of 116,429 female registered nurses residing across the United States who were enrolled
in 1989 at the age of 25–42 years (Fig. 1).5 At baseline, these women
completed a comprehensive questionnaire on lifestyle and medical factors and have since been followed biennially through mailed
questionnaires to collect updated exposure and disease information.
Diet was assessed in 1991 and updated every 4 years thereafter via
a validated semiquantitative food frequency questionnaire (FFQ). A
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Table 1 Outcomes that have been ascertained in the Nurses’ Health Study II cohort
Group

Health conditions

Cardiovascular disease

Coronary heart disease, stroke, high blood
pressure, cardiac arrest, congestive heart
failure, arrhythmia, elevated cholesterol,
peripheral artery disease, deep vein
thrombosis
Breast, colon or rectum, endometrium, ovary,
melanoma, basal cell skin cancer, squamous
cell skin cancer, other cancer
Colon or rectal polyp, ulcerative colitis/Crohn’s,
gastric or duodenal ulcer, Barrett’s esophagus,
gallstones, cholecystectomy
Emphysema/chronic bronchitis, asthma
Diabetes, obesity
Multiple sclerosis, Parkinson’s disease, depression
Fibrocystic/other benign breast disease,
endometriosis, kidney stones
Graves’ disease/hyperthyroidism, hypothyroidism,
hyperparathyroidism, gout, SLE (systemic
lupus), rheumatoid arthritis

Cancer
GI disease
Respiratory disease
Metabolic diseases
Mental and neurological disorders
Diseases of the genitourinary system
Immune diseases

These outcomes will continue to be tracked in the future, allowing fecal and oral microbiome to be associated cross-sectionally with currently prevalent cases and prospectively with
incident cases.

wide array of health conditions has been assessed by the biennial
questionnaires in combination with medical record review and/or
supplementary questionnaires in the NHS II (Table 1). Deaths have
been identified through the National Death Index, next-of-kin, and
postal authorities. The cumulative follow-up rate of the NHS II cohort is 94%, with approximately 112,000 participants in active follow-up as of May 2020.
In addition to questionnaire data, a comprehensive biorepository
has been established in the NHS II. Several types of biospecimens
have been collected during follow-up, including blood and urine sample collections in 1996–1999 (n = 29,611) and again in a subset of
these women from 2010 to 2011 (n = 14,600); buccal cell samples
collected in 2004–2006 from participants who did not provide blood
samples (n = 29,300); and tissue specimens from patients diagnosed
with incident cancers or premalignant lesions (n = 7,509, as of May
2020). Over the years, these samples have been used for genotyping
and assessment of numerous biomarkers through nested case–control studies, as well as deep molecular characterization of cancers.6–8
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Overview of the Micro-N project
The Micro-N project is designed to integrate microbiome characterization into epidemiologic research within the NHS II. Specifically,
it will enable us to prospectively characterize the determinants and
health effects of the microbiome, as well as its interactions with environmental and genetic factors in disease development and progression. In Micro-N, stool and tongue swab samples are collected for
gut and oral microbiome analysis from a targeted subset of 20,000
women under active follow-up (Fig. 2). To maximize the scientific
yield, we have prioritized historically underrepresented women and
women who have previously contributed other biospecimens (e.g.,
blood and urine) for genotyping and other profiling assays (e.g.,
metabolomics) to allow systematic interrogation of host–microbiota interactions. The study was approved by the institutional review
boards of the Brigham and Women’s Hospital and Harvard T. H. Chan
School of Public Health.
In 2017, on the biennial questionnaire, we asked participants if they
would be interested in providing a stool and oral sample if the collection was simple and relatively hygienic. Among the 83,695 participants
who responded, 55,215 (66%) women answered yes, of whom 42,093
(50%) said they would definitely participate and the other 13,122
(16%) would possibly participate. These responses support the feasibility to recruit and collect microbiome samples from at least 20,000
participants. The feasibility of this large-scale collection is further supported by two previous studies, the Men’s Lifestyle Validation Study
(MLVS)9,10 and the Mind Body Study (MBS).11 The MLVS included 308
men from a parallel cohort, the Health Professionals Follow-up Study
(HPFS), who provided up to four stool samples (two per week separated by 6 months) with additional data collected from two 7-day
diet records, two physical activity monitors, and two FFQs. The MBS
included 233 women from the NHS II who completed a detailed psychosocial assessment and were asked to self-collect stool samples
from two consecutive bowel movements (1–3 days apart) at two time
points 6 months apart. In the MBS, 213 (91%) women returned the
first set of kits and 206 (88%) returned the second set.
Among women from the main NHS II cohort who expressed their
willingness to participate, we conducted, via email, an enrollment
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Fig. 2 Workflow of the Micro-N project generalizable by the BIOM-Mass platform.
The Micro-N project aims to collect stool and oral microbiome samples from a target of 20,000 women in the NHS II, prioritizing racial minority groups and participants who have previously provided other biospecimens (e.g., blood, urine, and
buccal cells). In the process, we have developed a generalizable, scalable, and costeffective platform for microbiome specimen and metadata collection in large-scale
cohorts, the BIOM-Mass platform, implemented as part of the Harvard Chan Microbiome in Public Health Center (HCMPH) and the center’s Harvard Chan Microbiome
Collection Core (HCMCC). For Micro-N and similar studies employing the same platform, subjects are consented on paper or electronically, after which they are provided with a sampling kit (in person or by mail) containing up to four different specimen collection modalities: stool preserved in 95% ethanol, in an OMNIgene•GUT
kit, and viably in Anaerobe Systems liquid dental transport medium, and an oral
sample collected with an OMNIgene•ORAL kit. Kits can be returned by participants
through standard pre-paid mail, after which each non-anaerobic stool specimen
is aliquoted into a target of five ~500-μl subsamples and each oral specimen into
a target of two ~500-μl subsamples for molecular assays (amplicon sequencing,
metagenomics, metatranscriptomics, and/or metabolomics); and each anaerobic
stool sample can be used for downstream microbial isolation, culture, and/or gnotobiotics; or long-term (-80°C) storage.

survey to collect updated mailing and email addresses and to obtain
electronic consent (Fig. 2; Supplementary Methods 1). We also asked
participants whether they had had any overnight hospital visits or
lower endoscopic evaluations within the last 2 months, because of the
known influence of hospitalization12 and bowel preparations13,14 on the
gut microbiota. Participants who reported a hospitalization or colonoscopy in the past 2 months were held in the collection queue and
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approached for collection 2 months later. The collection kits with prepaid return postage were shipped by the US Postal Service (kit components are summarized in Supplementary Table 1).
We launched the collection in February 2019 with the support of
an infrastructure grant from the Massachusetts Life Sciences Center
(MLSC). Our collection began with a phased, 3-month ramp-up period in which we monitored both the rate of enrollment and consent
as well as the rate of kit return. In this period, kits were sent to 2,321
women, and 88% returned a kit within 2 months. As of 22 January
2021, we have sent kits to 17,464 women who had consented to participate and received the kits back from 14,731 women. We currently
project to complete the collection from 20,000 women by mid- August 2021. Based on the age distribution and disease rate in the NHS
II, we projected the number of incident cases of selected disease outcomes in 5, 10 and 15 years after the microbiome specimen collection in Micro-N (Table 2). Leveraging the ongoing follow-up of the
NHS II cohort, these estimations highlight the potential of Micro-N
for future prospective studies elucidating the role of the microbiome
in disease incidence.

Table 2 Projected number of incident cases of selected disease outcomes in 5, 10, and 15
years after the microbiome specimen collection in 20,000 NHS II women in Micro-N
Outcome
Diabetes
Stroke
Myocardial infarction
Breast cancer
Lung cancer
Colorectal cancer
Endometrial cancer
Ovarian cancer
Pancreatic cancer
Colorectal adenoma
Inflammatory bowel disease

No. of incident
cases in 5 years

No. of incident
cases in 10 years

No. of incident
cases in 15 years

510
168
149
190
130
101
81
48
30
579
43

925
373
293
408
274
204
149
91
66
1,069
87

1,210
595
418
623
410
299
197
127
103
1,397
124

The age-specific incidence rates for theses outcomes and total mortality rates observed in
older women in the NHS were used for the projection. Women in the Micro-N are assumed
to be a random sample of women in the overall NHS II cohort.
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Collection methods and kits provided by the BIOM-Mass
platform as part of the HCMCC
The specimen and metadata collection protocols developed for Micro-N have been formalized under the Harvard Chan Microbiome Collection Core (HCMCC) component of BIOM-Mass, a platform that we
developed, which also provides customizable fee-for-service implementations of these kits and processes for other large or small studies. As such, we sought to ensure that both fecal and oral specimen
collections were reliable, flexible, and scalable, and that a minimum
set of standardized participant information accompanies each collection. Although immediate freezing of stool samples at –20°C or below is often preferable for microbiome preservation, it is not feasible
for such large-scale field studies, leading to the development of alternative preservation methods for self-collected samples. Prior studies from our group and others have tested several different preservation methods, including RNAlater (Thermo Fisher), 90+% ethanol, 70%
ethanol, OMNIgene•GUT (DNA Genotek Inc.), Zymo DNA/RNA Shield
(Zymo Research), fecal occult blood test (FOBT) cards, fecal immunochemical test (FIT) tubes, and Whatman FTA cards (GE Healthcare).15–21
The predominant findings of these studies indicate that, for the subset of preservative methods meeting a minimum threshold for microbial fixation (i.e., the cessation of substantial metabolic activity), the
remaining effects of different preservatives and temperature regimes
on the microbial community profiles are small compared to interindividual variability.15–22 Through the use of preservatives, most of the
collection methods are able to prevent major compositional changes
in fecal microbial community when exposed to temperature fluctuations from 4°C–40°C over as many as 8 weeks, making them appropriate for home collection and a variety of shipment conditions.15–22
For Micro-N, stool and oral samples are thus self-collected by participants using the provided kits. Table 3 summarizes the applicable
downstream assays and stability evidence for the collection kits used
in Micro-N. For stool collection, to accommodate substantial biomass
for long-term biobanking and a variety of different downstream assays, we provide three different sample tubes. One tube includes 95%
ethanol, the second is the commercial OMNIgene•GUT kit, and third is
a cryovial pre-filled anaerobically with liquid dental transport medium
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Table 3 Applicable downstream assays and stability evidence for the collection kits used in Micro-N
Collection kit
Applicable downstream assays
						

Stability evidence for
field collectionsa

16S rRNA
MetaMetaMeta
Culture/
		
genomics transcriptomics bolomics
gnotobiotic
					
studies

Tested
conditions

Ref.

Up to 8 weeks at 4–40°C
28 days at room temperature
NA

37
38
NA

At least a week at room
temperature

39

Stool collection
95% ethanol
OMNIgene•GUT
Anaerobic kit

+
+
–

+
+
–

+
+
–

+
±
–

–
–
+

Oral sample collection
OMNIgene•ORAL
+
+
+
–
–
						

a. Stability data from validation studies showing the most extreme conditions (i.e., the longest interval between sampling collection and processing, and the most extreme temperature conditions).
+, yes; −, no; ±, uncertain.

(LDTM) (Anaerobe Systems). Together, these preservative options enable amplicon, shotgun metagenomic and metatranscriptomic sequencing, stool metabolomic profiling, in addition to future culture
and gnotobiotic animal model studies. Participants are asked to collect samples from the same bowel movement for all three tubes (Supplementary Methods 2). Briefly, once the toilet accessory has been
affixed to the commode, participants are asked to use the included
disposable spatula to transfer a small amount of stool into each collection tube up to a clearly marked, specified target level. After collection, participants are asked to shake the three tightly sealed tubes
for 30 seconds to allow adequate mixture of the samples with the stabilizing liquids. Upon finishing this collection, participants complete a
brief stool sample questionnaire (Supplementary Methods 3, and see
next section for further details) and affix barcode labels to the questionnaire and each tube.
We have validated our ethanol-based self-collection protocol in
the context of fecal metagenome and metatranscriptome profiling in
a pilot study of men enrolled in the HPFS.21 Participants self-collected
stool at home using both the Human Microbiome Project 1–validated
protocol (fresh frozen) and our collection kits using the US Postal Service for sample return. Consistent with 16S rRNA-based studies,15–20
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we demonstrated that self-collected stool using the preservatives in
our sample tubes (one tube with 95% molecular biology grade ethanol and one OMNIgene•GUT tube) provided statistically near-identical metagenomic data to frozen samples.21 The second iteration of the
Human Microbiome Project, the Integrative Human Microbiome Project (iHMP), and specifically the inflammatory bowel disease (IBD) cohort within iHMP, went on to use a similar protocol for self-collected
stool, additionally allowing untargeted metabolomic profiling in ethanol-preserved aliquots.23
For the accompanying oral sample collection, we use tongue swabs
from the OMNIgene•ORAL kit (DNA Genotek Inc.). The tongue microbiome can have somewhat greater microbial-to-human nucleotide
ratio variability between individuals but has decreased measurement
variability than other self-collectable oral locations (e.g., buccal swab,
saliva).24 Participants are asked to provide a tongue swab sample immediately upon waking on the day following the stool collection and
avoid eating, drinking, smoking, using mouthwash, or brushing teeth
prior to sample collection (Supplementary Methods 2). Participants
use the swab to gently rub the tongue for a minimum of 30 seconds,
immediately insert the swab into the bottom of the tube, and then
snap the shaft off at the break point, while leaving the swab tip in the
tube of liquid. To avoid contamination, participants are instructed not
to touch the swab tip to any other surface.
Once the tongue swab collection is finished, participants complete
an oral sample questionnaire (Supplementary Methods 3, and see next
section for further details) and mail all stool and oral collection kits
and questionnaires back to our laboratory using the pre-paid shipping box. Micro-N maintained a dedicated phone helpline and e-mail
address for participants who had specific questions, needed to ask for
replacement components, or were concerned they were not eligible
for participation because of a recent hospital procedure, disease diagnosis, or change in medication use. Among ~12,000 participants who
were consented and returned the collection kits by March 2020, we
estimate that we received contact queries from approximately 1,200
(10%) women. While Micro-N collection kits include four types of collection tubes, along with redundant copies of consumables (toilet accessories and spatulas), the HCMCC BIOM-Mass’s generalized protocol
allows cost-effective, modularized configuration of these kit components to enable study customization.
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Questionnaire development
To provide a minimum set of essential proximal exposure, outcome,
covariate, biometric, and technical information accompanying each
sample, we developed a set of standardized questionnaires (for stool
and oral collections, respectively) to accompany specimen collection
kits. The scannable (Scantron) questionnaires were developed through
collaboration with investigators from multiple institutions across the
United States that participated in a joint microbiome working group
for Micro-N (see Acknowledgements). To avoid overburdening participants and facilitate implementation in similarly time-limited settings, we limited questionnaire length to two pages for stool collection and one page for oral swab collection.
We employed an iterative process for questionnaire development.
First, we identified major domains for assessment through literature
review of microbiome determinants, complemented by reference to
existing questionnaires that were shared within the working group.
Seven domains were identified for the stool questionnaire, including
the timing of collection, stool consistency, bowel movement pattern,
diet, major lifestyle factors, medication use and medical history. For
the oral questionnaire, five domains were identified, including the timing of collection, use of the oral hygiene products, natural teeth, history of dental cleaning and surgery, and periodontal disease history.
Then, for each of the domains we developed one or more potential
questions that were subsequently discussed among the group to refine wording and response options. These discussions also identified
the time frames most relevant to the microbiome for each question.
After completing the draft questionnaires, we presented them to the
working group and made further modifications based on feedback.
In the end, a total of 12 overarching questions were included in each
of the stool and oral questionnaires (some contained relevant subquestions, e.g., diet and medications; the questionnaires are presented
in Supplementary Methods 3; the rationales and considerations for
questionnaire development are summarized in the Supplementary
Discussion). Of note, the questions did not include those that have already been queried in the main follow-up questionnaires in the NHS
II or do not change over time. Major categories of these previously
ascertained factors are early-life driving forces for the establishment
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of the microbiome, including mode of delivery, breastfeeding, and
household exposures (e.g., siblings and pets),25,26 which have been included on the generalized forms of these questionnaires supported
by HCMCC for other population studies.
Sample processing and storage
After return via US mail, kits are received and their components (questionnaires and specimens) tracked using the matched, affixed barcodes. This allows technical considerations such as kit incompleteness
or damage to be recorded as well. For all received kits, standardized
questionnaires are set aside to be coded, scanned, and programmed
with existing algorithms validated in the parent NHS II study. Stool
and oral specimens are loaded onto a laboratory information management system (LIMS) (LabVantage)-integrated, Hamilton Microlab
STAR liquid handling robot (Fig. 2). This permits pre-separation into
multiple ~500-μl aliquots per sample prior to storage, preventing the
need for freeze-thaw cycles prior to assays at various times in the future. By matching specimen, questionnaire, LIMS, and aliquot cryovial
barcodes, batched aliquot racks are then automatically loaded into a
Hamilton BiOS robotic freezer for long-term storage at -80°C.
This storage environment permits automated retrieval of any aliquot subset based on sample type, collection date, subject characteristics, or other information recorded in the Micro-N LIMS or the
parent NHS II study. Retrieval is executed and tracked automatically
by the freezer, and successfully retrieved aliquots can be transferred
directly for experimental work (e.g., for culturing or gnotobiotics), or
shipped to molecular data generation facilities (for amplicon sequencing, metagenomics, metatranscriptomics, and/or metabolomics). Critically, this infrastructure permits long-term parent and child sample
linkage with their contributing cohort participants and associated information. For example, should a population-level study result in the
isolation of a microbial strain of interest, the isolate, its parent specimen, associated molecular data, and the medical history of its original donor are all available through the integrated biorepository, NHS
II cohort infrastructure, and BIOM-Mass data portal.
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The BIOM-Mass data portal
Finally, the BIOM-Mass Data Portal (http://portal.biom-mass.org ) is an
in-house data-sharing portal provided by the Harvard Chan Microbiome in Public Health Center (HCMPH) to manage and share microbiome profiles, sample, and population information from microbiome
epidemiology studies carried out through the HCMPH BIOM-Mass
platform, including Micro-N. It supports both open- and controlledaccess dissemination of microbiome multi-omics (16S rRNA gene amplicon profiles, metagenomes, metatranscriptomes, metabolomes,
etc.), raw and processed data products (sequences, taxonomic profiles, functional profiles, etc.), and sample and subject covariates (phenotypes, demographics, biometrics, technical protocols, etc.). Data can
be shared publicly, controlled- access, or securely protected on a project-specific basis. Only microbial information (i.e., non-human genetic
material) are shared, and sensitive covariates can be stripped, linked
from an external database such as dbGaP, or secured for individual
projects by Google Cloud Platform authentication. The Data Portal
builds on technology from the Human Microbiome Project Data Coordinating Center (http://ihmpdcc.org )1 and the Genomic Data Commons (https://gdc.cancer.gov )27 and is integrated with the Terra platform (https://terra.bio ) for ’omics data dissemination. The BIOM-Mass
Data Portal is particularly tailored to provide raw and processed microbiome epidemiological profiles and accompanying phenotypes
and covariate annotations, including for large, controlled-access projects such as Micro-N.
Summary and future prospects
The advent of inexpensive, widely available microbial community
assays (particularly high-throughput, next-generation sequencingbased approaches) has underscored the extent to which prospectively banked human microbiome specimens would benefit existing
long-running cohorts. With Micro-N, BIOM-Mass, the associated protocols, and the resources of the HCMPH, we aim to future-proof the
NHS II and other largescale epidemiologic studies for future developments in microbiome science, while also driving near-term discoveries
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in mechanism, causality, and public health. Although long-term (and
especially early life) exposures are viewed as dominant driving forces
for the microbiota’s substantial interindividual variation,28–30 short-term
exposures also have critically important consequences (e.g., antibiotics)31,32 and the specific effects of many such exposures on the microbiome remain to be established. Addressing these significant knowledge
gaps requires prospective investigations with high-quality exposure
data collected over the life course, with microbial composition and
function assessed prior to disease onset.
The Micro-N project’s large-scale microbiome specimen collection
within the NHS II will provide unparalleled opportunities for future
prospective studies to interrogate the role of the microbiome in human health and disease, as well as the interplay between environmental factors, genetics and other host characteristics, and the microbiome in disease development and progression. It has also served to
establish a scalable, generalizable, and validated protocol for microbiome epidemiology, implemented by and available from the HCMCC,
BIOM-Mass, and the HCMPH. Any such investigations can take advantage of the efficient sampling design of nested case–control studies,
in which incident cases diagnosed after specimen collection and their
matched controls are identified for microbiome assessments. These
data can then be pooled to study the long-term influence on the microbiome of lifestyle, genetic and environmental exposures over the
life course. While the NHS II is limited by its inclusion of female participants only, the generalizable protocol we are using allows for future
pooled analysis of data from other cohorts and different study populations.33–35 Moreover, although the current protocol covers sample
collection at a single time-point, the established infrastructure in the
NHS II cohort allows for future repeated collections from these participants. Finally, 27,706 children of the NHS II participants between
the ages of 9 and 17 years have been enrolled and followed up since
1996 in another prospective cohort, the Growing Up Today Study
(GUTS)36 offering opportunities for transgenerational studies. Therefore, we anticipate that the Micro-N project will provide the ideal setting to elucidate how host, environment, and the microbiome interact with each other to influence health, facilitating development of
microbiota-targeted preventives, diagnostics, and therapeutics.
*

*

*

*
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